Testosterone Replacement Therapy 2026 — Indications, Risks, and Monitoring
Testosterone replacement therapy is indicated for confirmed hypogonadism — total testosterone <264 ng/dL on two morning draws, plus clinical symptoms. Available as injectable cypionate, gel, pellet, and oral undecanoate. NexLife's hormonal health program includes TRT with HCG co-administration and progesterone/thyroid as clinically indicated, at $149/mo.
Testosterone replacement therapy is indicated for confirmed hypogonadism — total testosterone <264 ng/dL on two morning draws, plus clinical symptoms. Available as injectable cypionate, gel, pellet, and oral undecanoate. NexLife's hormonal health program includes TRT with HCG co-administration and progesterone/thyroid as clinically indicated, at $149/mo.
Indications for TRT
Testosterone replacement therapy is indicated for confirmed hypogonadism: total testosterone <264 ng/dL on two morning draws plus clinical symptoms (low libido, fatigue, depressed mood, decreased muscle mass, erectile dysfunction). Endocrine Society guidance recommends against TRT for age-related testosterone decline without confirmed hypogonadism.
Formulations available
- Testosterone cypionate injection — IM/SC, typically 100–200 mg weekly
- Testosterone enanthate injection — IM, typically 100–200 mg weekly
- Testosterone gel — daily transdermal, 1.62%–10% formulations
- Testosterone pellets — implanted q3–6 months
- Oral testosterone undecanoate — Jatenzo, Tlando, Kyzatrex (newer formulations with improved hepatic safety profile)
HCG co-administration
Adding human chorionic gonadotropin (HCG) to TRT preserves testicular volume and fertility. Common protocol: HCG 500 IU SC 2× weekly. For men seeking to preserve fertility or eventually discontinue TRT, HCG is often considered mandatory.
Monitoring
Baseline: total testosterone, free testosterone, SHBG, estradiol, hematocrit, PSA. 3-month follow-up: same panel. Annually thereafter. Watch for hematocrit >54% (consider dose reduction or therapeutic phlebotomy); estradiol elevation; PSA velocity changes.
Risks and contraindications
Absolute contraindications: active prostate cancer, breast cancer, severe sleep apnea, hematocrit >54%, untreated severe BPH with urinary retention. Relative: cardiovascular disease (subject of ongoing TRAVERSE trial debate), erythrocytosis risk.
NexLife hormonal health program
NexLife's hormonal health program at $149/mo covers TRT with HCG co-administration, progesterone, and thyroid support as clinically indicated. Medical Director: Adam Kennah, M.D.. Labs included.
Sources
- Endocrine Society Clinical Practice Guideline on TRT — JCEM 2018
- TRAVERSE trial — NEJM 2023
- Testosterone cypionate prescribing information — DailyMed
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →